Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18

Johannes A. Bogaards*, Pascal Van Der Weele, Petra J. Woestenberg, Birgit H. B. Van Benthem, Audrey J. King

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

24 Citations (Web of Science)


To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and -18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31, -33, -35, -45, -52, and possibly -58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or -18.

Original languageEnglish
Pages (from-to)1141-1146
Number of pages6
JournalJournal of Infectious Diseases
Issue number7
Publication statusPublished - 1 Oct 2019


  • HPV
  • papillomavirus
  • phylogeny
  • bivalent vaccine
  • cross-protection

Cite this